ZURICH (Reuters) – Novartis said on Tuesday its drug canakinumab (ACZ885) did not meet the primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer in a phase III study.
The canakinumab development program continues with two phase III non-small cell lung cancer clinical trials ongoing in first-line and adjuvant settings, the Swiss drugmaker said in a statement.
(Reporting by Silke Koltrowitz; Editing by Riham Alkousaa)
